Profile: Concert Pharmaceuticals Inc (CNCE.OQ)

CNCE.OQ on NASDAQ Stock Exchange Global Market

1:30am IST
Change (% chg)

$-0.12 (-1.09%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Concert Pharmaceuticals, Inc., incorporated on April 12, 2006, is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drugs. The Company operates through the development of pharmaceutical products on its own behalf or in collaboration with others. The Company's deuterated chemical entity platform (DCE Platform), has potential across various therapeutic areas. Its product candidates include AVP-786, CTP-656, CTP-730, CTP-543 and JZP-386.

The Company's product candidate, CTP-656, is a next generation potentiator that the Company is initially developing for the treatment of cystic fibrosis in patients having gating mutations, including the G551D mutation. CTP-656 is discovered by applying the Company's deuterium chemistry technology to modify ivacaftor. Food and Drug Administration (FDA) granted orphan drug designation for CTP-656. It has initiated a Phase II clinical trial evaluating CTP-656 in patients having gating mutations, including the G551D mutation. CTP-543 was discovered by applying Concert's deuterium chemistry technology to modify ruxolitinib. The Company has completed single and multiple ascending dose Phase I trials for CTP-543. It also conducted a Phase I crossover study evaluating the metabolite profiles of CTP-543 and ruxolitinib.

The Company's product candidate, AVP-786, is a combination of a dextromethorphan and an ultra-low dose of quinidine. It has initiated the Phase III clinical program to evaluate the safety and efficacy of AVP-786 for the treatment of agitation associated with Alzheimer's disease. In addition, it is conducting multiple Phase II trials exploring additional neurological indications. CTP-730 is a phosphodiesterase 4 (PDE4) inhibitor that has potential for the treatment of various inflammatory diseases. CTP-730 is a deuterated analog of apremilast. It has completed the Phase I clinical evaluation of CTP-730. JZP-386 is a deuterated analog of sodium oxybate, which is being developed for the treatment of excessive daytime sleepiness and cataplexy in patients with narcolepsy. The Company has completed a Phase I clinical study for JZP-386.

The Company competes with Teva Pharmaceutical Industries Ltd. and DeuteRx LLC.

Company Address

Concert Pharmaceuticals Inc

65 Hayden Ave Ste 3000N
LEXINGTON   MA   02421-7994
P: +1781.8600045
F: +1302.6365454

Company Web Links